The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by ...

BEIJING--(BUSINESS WIRE)--Novo Holdings, a leading global life science investor, and KKR, a leading global investment firm, today announced the signing of definitive agreements under which Novo ...

BioBridges adds job growth to the Raleigh-Durham area BioBridges, a leading provider of life sciences solutions, has brought more than 20 n ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses. In a prior call, a viewer asked about Novo Nordisk A/S ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy. The European Union drug ...

It isn't wise to count out this veteran pharmaceutical company, however. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why.

Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy ...

annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B "At Novo Nordisk, we believe understanding the whole person and their journey is ...